40th week of 2017 patent applcation highlights part 10 |
Patent application number | Title | Published |
20170281515 | INHIBITING COLOR FADING WITH LAYER-BY-LAYER FILMS - The present disclosure relates to methods for inhibiting color fading in hair and for improving the color durability and stability of artificial color of hair. The methods entail forming a layer-by-layer (LbL) film on hair, and optionally forming a cationic surface layer on the LbL film. The LbL film is formed by applying a cationic silane layer on the hair and subsequently applying an anionic polymer layer on the cationic silane. Multiple cationic silane layers and anionic polymer layers can sequentially be added as desired. Finally, the LbL film may comprise a cationic surface layer. | 2017-10-05 |
20170281516 | METHOD FOR PRODUCING FUNCTIONAL LUBRICANT AND PARTICULATE MATERIAL SET USED IN THE METHOD - A method for producing a functional lubricant includes mixing particulate sodium polyacrylate alone with water, adding a particulate carbonate which is any one or more of sodium bicarbonate, sodium carbonate, and calcium carbonate and a particulate carboxylic acid which is any one or more of citric acid, lactic acid, malic acid, tartaric acid, succinic acid, fumaric acid, and maleic acid to the water containing the sodium polyacrylate to produce carbon dioxide, and allowing the sodium polyacrylate to disperse without stirring the water to produce a functional lubricant containing the sodium polyacrylate serving as a sole lubricant base. The weight ratio of the sodium polyacrylate to the carbonate and to the carboxylic acid is from 5:1:1 to 8:1:1. | 2017-10-05 |
20170281517 | SWEAT-INHIBITING AND/OR DEODORIZING COSMETIC AGENTS WITH LOW EMULSIFIER CONTENT - The present invention relates to cosmetic agents having a low emulsifier content which include a combination of a specific non-ionic polyurethane polymer and at least two emulsifiers having different HLB values. The aforementioned cosmetic agents, in spite of the low emulsifier content, have a high storage stability and also good applicability and dosing accuracy. In addition, these agents are particularly skin-friendly. The present invention also relates to a method for preventing and/or reducing perspiration of the body with use of a cosmetic agent according to the invention, and also to the use of the cosmetic agent according to the invention for increasing the skin compatibility and/or for reducing and/or preventing textile discoloration and/or textile stains. | 2017-10-05 |
20170281518 | LIP COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO LIPS - Lip compositions, in particular lip gloss compositions, capable of forming a multilayer structure after application to lips are provided, as well as methods of applying such compositions to lips. | 2017-10-05 |
20170281519 | COSMETIC COMPOSITIONS COMPRISING SILICONE CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIAL - Cosmetic compositions capable of forming a multilayer structure after application to a keratinous material are provided, as well as methods of applying such compositions to a keratinous material. Certain cosmetic compositions comprises at least two immiscible components: Component A which comprises about 0.01% to 60% by weight with respect to the total weight of the composition of at least one silicone-containing film forming agent having at least one glass transition temperature which is lower than normal human body temperature; and Component B which comprises about 0.01% to 90% by weight with respect to the total weight of the composition of one or more silicone compounds in amounts sufficient to achieve a viscosity of about 1,000 cSt to 10,000,000 cSt, wherein the weight ratio of silicone-containing film forming agent(s) in Component A to silicone compound(s) in Component B is from about 1:50 to 50:1. | 2017-10-05 |
20170281520 | LIP COMPOSITIONS - Lip compositions, in particular lip oil compositions, capable of forming a multilayer structure after application to lips are provided, as well as methods of applying such compositions to lips. | 2017-10-05 |
20170281521 | COSMETIC COMPOSITIONS COMPRISING SILICONE AND HYDROCARBON CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIAL - Cosmetic compositions capable of forming a multilayer structure after application to a keratinous material are provided, as well as methods of applying such compositions to a keratinous material. Certain cosmetic compositions comprises at least two immiscible components: Component A which comprises about 0.01% to 60% by weight with respect to the total weight of the composition of at least one hydrocarbon-containing film forming agent having at least one glass transition temperature which is lower than normal human body temperature; and Component B which comprises about 0.01% to 90% by weight with respect to the total weight of the composition of one or more silicone compounds in amounts sufficient to achieve a viscosity of about 1,000 cSt to 10,000,000 cST, wherein the weight ratio of hydrocarbon-containing film forming agent(s) in Component A to silicone compound(s) in Component B is from about 1:50 to 50:1. | 2017-10-05 |
20170281522 | HAIR CARE COMPOSITIONS COMPRISING CATIONIC COMPOUNDS, STARCH, AND SILANE COMPOUNDS - Disclosed are compositions for treating and conditioning keratinous substrates, comprising a cationic agent comprising quaternary ammonium compounds; a modified starch; silane compounds, a cationic vinylpyrrolidone polymer and water. Also disclosed are methods treating and conditioning keratinous substrates using the composition. | 2017-10-05 |
20170281523 | COMPOSITION FOR FAST DRY OF HAIR - The present invention discloses a hair conditioner composition comprising a) from about 0.15% to about 16% moisture control material or mixtures of moisture control materials wherein one or more moisture control material is selected from the group containing:
| 2017-10-05 |
20170281524 | COSMETIC HAIRCARE PRODUCT FOR THE STRAIGHTENING OF HAIR IN SHAMPOO FORMAT - A cosmetic haircare product for the straightening of hair in shampoo format, belonging to the technical field of cosmetics, is disclosed. The shampoo is ready to be used in a single step, and comprises: Water, Sodium Laureth Sulphate, Lactic Acid, Glycolic Acid, Glyoxylic Acid, Cocamide DEA, Cocamidopropyl Betaine, Salicylic Acid, Glycol Distearate, Thioctic acid, Perfume (fragrance), Mica CI 77019, CI 77891, D-Limonene, Linalool, Propylene glycol, Hexyl cinnamal, Sodium hyaluronate, Butylphenyl methylpropional, DMDM hydantoin and Phenoxyethanol. Its method of use is also disclosed. | 2017-10-05 |
20170281525 | BODILY LUBRICATING AND MOISTURIZING COMPOSITIONS CONTAINING PLANT MUCILAGE - A body lubricating and moisturizing formulation utilizes a mucilage-containing extract derived from a plant such as okra, | 2017-10-05 |
20170281526 | METHOD FOR PROVIDING A CUSTOMIZED SKIN CARE PRODUCT TO A CUSTOMER - A method for providing a customized skin care product to a customer and skin care kit are disclosed. The method includes obtaining information from a customer regarding current skin conditions, analyzing the information to identify a plurality of target skin conditions in response to the current skin conditions, correlating booster compositions to the target skin conditions, the booster compositions including active ingredients corresponding to the target skin conditions, and assembling a skin care kit, the skin care kit including a base oil composition and a plurality of booster compositions having actives corresponding to the target skin conditions. The base oil composition and plurality of boosters are mixable to obtain a treatment composition at any point in time prior to application to skin. | 2017-10-05 |
20170281527 | MINERAL BASED COMPOSITIONS AND USE THEREOF - Mineral-based composition and methods of use thereof in preventing skin damages, such as in subjects exposed to radiation, are provided. | 2017-10-05 |
20170281528 | Hair Follicles Made Ex Vivo That Can be Inserted into a Recipient for Hair Restoration - The present invention recognizes that there exists a long felt need for reliable hair growth methods and compositions that do not suffer from side effects and limitations of current technologies, such as surgery using a subject's own hair and pharmaceutical compositions. A first aspect of the present invention is a method of making at least one three dimensional collection of cells capable of forming a functional hair follicle. A second aspect of the present invention is a product produced by the method of making at least one three dimensional collection of cells capable of forming a functional hair follicle of the present invention. A third aspect of the present invention is a method of making at least one functional hair follicle. A fourth aspect of the present invention is a product produced by the method of making at least one functional hair follicle of the present invention. A fifth aspect of the present invention is a method of hair growth in a subject using at least one three dimensional collection of cells capable of forming a functional hair follicle of the present invention. A sixth aspect of the present invention is a method of hair growth in a subject using at least one functional hair follicle of the present invention. | 2017-10-05 |
20170281529 | Formulations - In a metered dose inhaler, comprising a canister and metering valve, containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant, a method of reducing deposition of particles on the surfaces of the canister and the metering valve, the method comprising the step of adding a wetting agent to the formulation. | 2017-10-05 |
20170281530 | SYSTEMS AND METHODS FOR PRODUCING HOMOGENOUS PHARMACEUTICAL COMPOSITIONS - Embodiments of the present disclosure generally relate to systems and methods for mixing pharmaceutical compositions, agents and/or ingredients together. In one embodiment, a method can include a shell and a flexible pouch disposed within the shell. The flexible pouch can include at least one active pharmaceutical ingredient and at least one delivery agent. Further, the flexible pouch and the shell can be configured to receive a dispensing member for dispensing a predetermined amount of a pharmaceutical composition. Methods can also include subjecting the container to high intensity vibrations for a predetermined mixing time to produce the pharmaceutical composition. | 2017-10-05 |
20170281531 | CRANIAL DELIVERY OF PHARMACEUTICALS - A method for rapid delivery of an active compound to innervate a cranial nerve of a subject. Also provided is a method for treating a disease or condition by topically applying a pharmaceutical composition to the face excluding the palpebral part of the eye, in an amount effective for treating the disease or condition. | 2017-10-05 |
20170281532 | 2 SUBSTITUTED CEPHEM COMPOUNDS - The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same. | 2017-10-05 |
20170281533 | INTRAVENOUS ADMINISTRATION OF TRAMADOL - A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol). | 2017-10-05 |
20170281534 | ADMINISTRATION OF INTRAVENOUS IBUPROFEN - An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia. | 2017-10-05 |
20170281535 | METHOD AND DEVICE FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE USING A MICROPROJECTION ARRAY - A method and a drug delivery system for transdermally administering parathyroid hormone (PTH) in a pulsatile fashion are provided, where the drug delivery system comprises an array of microprojections each comprising PTH. | 2017-10-05 |
20170281536 | DEGRADABLE NETWORKS FOR SUSTAINED RELEASE AND CONTROLLED RELEASE DEPOT DRUG DELIVERY APPLICATIONS - Provided herein is a controlled release and/or sustained release depot drug delivery system, comprising, a biodegradable polymer coating and an API coated with the biodegradable polymer coating, wherein a quantity of API coated with biodegradable polymer is effective to be released. from the biodegradable polymer coating over a prolonged period of time. | 2017-10-05 |
20170281537 | LIPID FORMULATIONS COMPRISING A THIOLATED ANTIOXIDANT - The present invention provides a formulation comprising a lipid matrix; at least one thiolated antioxidant; at least one bioactive agent; and optionally at least one chelating agent. The bioactive agent may be a gonadotrophin-releasing hormone (GnRH) agonist; a gonadotrophin-releasing hormone (GnRH) antagonist; a luthenizing hormone releasing hormone (LHRH); and/or a luthenizing hormone releasing hormone (LHRH) related peptide. | 2017-10-05 |
20170281538 | DIETARY SUPPLEMENT NON-FLUORIDE TOOTHPASTE AND METHODS OF MAKING AND USING SAME - Provided herein is a storage stable non-fluoride toothpaste composition enriched with a dietary supplement containing both oil soluble and water soluble vitamins. The dietary supplement is incorporated into the toothpaste, the dietary supplement containing a water soluble vitamin portion including at least one water soluble vitamin and an oil soluble vitamin portion. The oil soluble vitamin portion includes at least one oil soluble vitamin, a carrier oil and an emulsifier. The toothpaste is thereby formulated in a manner such that oral application will result in systemic delivery of at least a portion of the dietary supplement to meet a 2% RDI threshold even when 3 or less serving sizes are orally applied. | 2017-10-05 |
20170281539 | Method for manufacturing medicated chewing gum without cooling - An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described. | 2017-10-05 |
20170281540 | COMPOSITION OF MATTER COMPRISING LIPOSOMES EMBEDDED IN A POLYMERIC MATRIX AND METHODS OF USING SAME - The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes. The present disclosure also provides a method of removal of non-encapsulated active agent from the composition of matter, a method of preparing said composition of matter, a pharmaceutical composition comprising said composition of matter, use of such composition of matter; a method of providing prolonged delivery of a active agent to a subject in need thereof by administering to said subject the composition of matter disclosed herein as well as a package comprising said composition of matter held within said aqueous medium and instructions for use thereof. | 2017-10-05 |
20170281541 | LIPOSOME-BASED MUCUS-PENETRATING PARTICLES FOR MUCOSAL DELIVERY - Liposome-based mucus-penetrating particles (MPP) capable of loading hydrophilic agents including therapeutic, prophylactic and diagnostic agents such as the diaCEST MRI contrast agent barbituric acid (BA) were evaluated to determine how to optimize delivery. Polyethylene glycol (PEG)-coated liposomes containing ≧7 mol % PEG diffused only approximately 10-fold slower in human cervicovaginal mucus (CVM) compared to their theoretical speeds in water. 7 mol %-PEG liposomes provided improved vaginal distribution compared to 0 and 3 mol %-PEG liposomes. | 2017-10-05 |
20170281542 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA - The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: | 2017-10-05 |
20170281543 | METHOD FOR PRODUCING LIPOSOME AND APPARATUS FOR PRODUCING LIPOSOME - Disclosed herein are a method for producing a miniaturized liposome on a large production scale, and an apparatus for producing a liposome which is to be used in the above-mentioned method. Provided is a method for producing a liposome, including a step of stirring a mixture containing an oil phase in which at least one lipid is dissolved in an organic solvent and a water phase in a first tank of an apparatus having the first tank and a circulation path, in which the ratio of the capacity of the circulation path to the total capacity of the tank and the circulation path is 0.4 or less and/or the time required for the mixture to return to the first tank after being discharged therefrom is within 2.0 minutes. | 2017-10-05 |
20170281544 | OXYGEN-ENABLED COMPOSITION - A composition of chlorine-free poly-oxygenated aluminum hydroxide that comprises a clathrate containing oxygen gas molecules, In one embodiment, the poly-oxygenated aluminum hydroxide has particles having a diameter of 212 microns or less. The composition may be homogeneous. | 2017-10-05 |
20170281545 | Immunomodulation Using Spores and Pollen Grains - The present invention includes compositions, methods of making and using the compositions for modulating the immune response in a subject by providing a vaccine composition having a pollen or spore disposed in a pharmaceutical carrier for delivery to a subject, wherein the pollen or spore comprises multiple pores that connect an outer surface of the pollen/spore to an inner cavity and one or more antigens disposed on the outer surface, in the inner cavity, in the multiple pores, or a combination thereof, wherein the one or more antigens modulate an immune responses in the subject. | 2017-10-05 |
20170281546 | TAURINE COMPOSITIONS SUITABLE FOR INHALATION - The invention discloses spray-dried compositions for inhalation and methods for preparing such powder compositions. The compositions of the invention are produced by spray-drying taurine under conditions that (i) retain the physical and chemical stability of the composition during spray drying and upon storage, (ii) protect the powder composition from aggregation and (iii) provide particles suitable for aerosolisation. | 2017-10-05 |
20170281547 | PREPARATION OF PEPTIDE LOADED PLGA MICROSPHERES WITH CONTROLLED RELEASE CHARACTERISTICS - A novel process for the preparation of a long acting injectable composition based on biodegradable poly(D,L-lactide-co-glycolide) microspheres comprising peptide active pharmaceutical ingredients. | 2017-10-05 |
20170281548 | Organic Compounds - A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane. | 2017-10-05 |
20170281549 | METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF CRYSTALLINE MICROPARTICLE SURFACES FOR ACTIVE AGENTS - Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties. | 2017-10-05 |
20170281550 | COMPRESSIBLE AND FREE-FLOW CO-AGGLOMERATES OF MANNITOL AND GRANULAR STARCH - Co-agglomerates of crystalline mannitol and granular starch, characterised in that they have a compressibility, as determined according to a test A, higher than 120 N, and preferably of 200 to 450 N, and a flow time, as determined according to a test B, of 3 to 15 seconds, and preferably of 4 to 8 seconds. | 2017-10-05 |
20170281551 | SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION - This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer. | 2017-10-05 |
20170281552 | POWDERY MATERIAL MIXING DEGREE MEASUREMENT DEVICE, POWDERY MATERIAL MIXING AND FEEDING SYSTEM, AND COMPRESSION-MOLDING MACHINE INCLUDING THE SAME - A powdery material mixing degree measurement device includes a discharger configured to discharge mixed powdery materials to a filler configured to fill, with the powdery materials, a vertically penetrating die bore of a compression-molding machine including a table including the die bore, a slidable lower punch including an upper end inserted to the die bore, and a slidable upper punch including a lower end inserted to the die bore, a plurality of movable portions configured to move the mixed powdery materials to the discharger, and a sensor configured to measure a mixing degree of the mixed powdery materials in the movable portions. | 2017-10-05 |
20170281553 | FILM COATING COMPOSITION AND METHODS OF MAKING AND USING THE SAME - A film coating composition comprising a cellulosic polymer, an opacifying agent, and a fatty acid is disclosed herein. Also disclosed is a film coating composition comprising a cellulosic polymer, an opacifying agent, a plasticizing agent, and a polyol. The disclosed film coating compositions may be mixed with a solvent to produce a film coating suspension. The film coating suspension can be applied to a substrate, such as a nutritional supplement, pharmaceutical, tablet, capsule, softgel, granule, particle, food confectionary form, agricultural seed, and the like to form a film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided. | 2017-10-05 |
20170281554 | SYSTEM FOR UPPER INTESTINAL DELIVERY OF ACTIVE INGREDIENTS - A preparation for releasing an active substance, such as iron, in the upper intestine includes an oral dosage form having an external coating, a coating matrix enveloping the oral dosage form, and the active substance embedded in the coating matrix. The active substance disintegrates from the coating matrix within at least one of the stomach, duodenum, upper jejunum, or any combination thereof. | 2017-10-05 |
20170281555 | GASTRIC REFLUX RESISTANT DOSAGE FORMS - Gastric resistant film-forming compositions are described herein. The composition contains a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (SOFLET®) containing an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally. | 2017-10-05 |
20170281556 | ORAL PHARMACEUTICAL DOSAGE FORMS OF BUDESONIDE - The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease. | 2017-10-05 |
20170281557 | DRUG-CONTAINING PARTICULATE COMPOSITION WITH CATIONIC AGENT, ASSOCIATED MEDICAL DEVICES, AND METHODS FOR TREATMENT - The disclosure provides bioactive agent-containing particulates that include bioactive agent, biocompatible polymer, negatively charged groups, and a cationic agent. The particulates can be associated with a medical device, such as a balloon catheter, which can be used to move the particulates to a treatment site. Transfer of the particulates from the device to tissue is facilitated by the arrangement of the cationic and bioactive agent-containing particulates. | 2017-10-05 |
20170281558 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AN AQUEOUS SUSPENSION OF MICROCAPSULES FOR THE MODIFIED RELEASE OF ACTIVE PRINCIPLE(S). - The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s). | 2017-10-05 |
20170281559 | STEALTH, TARGETED NANOPARTICLES (STN) FOR ORAL DRUG DELIVERY - The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions. | 2017-10-05 |
20170281560 | SYSTEMS AND METHODS OF ON-DEMAND CUSTOMIZED MEDICAMENT DOSES BY 3D PRINTING - Systems and methods of fabricating a customized dose using a medication 3D printer are provided. According to one embodiment, a system is provided that includes a 3D printer that receives prescription dose instructions from a computer or mobile communication device via a network and assembles a customized medication dose according to the prescription dose instructions by selective application of materials stored in a medicament compound container having at least one reservoir containing the materials for assembly. The materials for assembly can be provided to the 3D printer by a master conduit connecting reservoirs in the medicament compound container to the 3D printer. The 3D printer accesses specified amounts of the materials, which include medicament compounds, via the master conduit, and assembles the customized medication dose according to the prescription dose instructions. | 2017-10-05 |
20170281561 | DRUG DELIVERY FABRIC HAVING DRUG-CONTAINING LAYER - The present invention relates to a drug delivery fabric having a drug-containing layer, wherein the drug delivery fabric comprises a surface layer, a middle layer, and a drug-containing layer, the middle layer is formed of a yarn having hydrophilicity relatively equal to or higher than that of the surface layer, the drug-containing layer is formed of a cellulose derivative film containing a drug. | 2017-10-05 |
20170281562 | PHARMACEUTICAL COMPOSITIONS - The invention provides transdermal patches comprising an adhesive and a composition comprising naltrexone and methyl oleate or isopropyl myristate, a kit comprising a plurality of such transdermal patches, a composition comprising naltrexone and methyl oleate, such a composition for use as a medicament, and compositions comprising naltrexone and methyl oleate or isopropyl myristate for use in the treatment of alcoholism or opiate addiction. | 2017-10-05 |
20170281563 | METHOD OF REDUCING SCARRING - A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin. | 2017-10-05 |
20170281564 | THERAPEUTIC ASTAXANTHIN AND PHOSPHOLIPID COMPOSITION AND ASSOCIATED METHOD - A dietary supplement includes comprising a therapeutic amount of astaxanthin derived from a synthetic or natural ester or diol, and at least one of a phospholipid, glycolipid, and sphingolipid, and formulated into an oral dosage form, wherein the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid. The composition includes 0.5 to 12 mg of astaxanthin and may be used to treat low density lipoprotein (LDL) oxidation in humans and other diseases, disorders and impairments. | 2017-10-05 |
20170281565 | Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject. | 2017-10-05 |
20170281566 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES - The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients | 2017-10-05 |
20170281567 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS - The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC). | 2017-10-05 |
20170281568 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE - The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol. | 2017-10-05 |
20170281569 | METHOD FOR ENHANCING IMMUNE CELL FUNCTION AND METHOD FOR ASSESSING IMMUNE CELL MULTIFUNCTIONALITY - The invention provides a method for enhancing immune cell function by activating various immune cells ex vivo and provides immune cells with enhanced function. The invention further provides an immune-related cell multifunctionality evaluation method. A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is capable of enhancing immune cell multifunctionality by increasing CD8+T cells having a high ability to produce IL-2, INFα, and IFNγ. The immune-related cell multifunctionality may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug selected from metformin, phenformin, and buformin, with control immune cells untreated with the biguanide antidiabetic drug. When the multifunctionality of immune cells treated with the biguanide antidiabetic drug selected from metformin, phenformin, and buformin is determined to be significantly increased compared with the control, it can be evaluated that the sensitivity of the immune cells to the therapeutic agent is improved. | 2017-10-05 |
20170281570 | TOPICAL AND TRANSDERMAL DELIVERY OF HIF-1 MODULATORS TO PREVENT AND TREAT CHRONIC WOUNDS - Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound. | 2017-10-05 |
20170281571 | METHODS FOR THE TREATMENT OF ROSACEA - The present invention relates to pharmaceutical compositions for topical use (including also dermatological compositions), for treating skin conditions and afflictions, such as rosacea and symptoms and conditions associated there from. | 2017-10-05 |
20170281572 | FORMULATION FOR TREATING CHRONIC WOUNDS - Inventive subject matter disclosed herein includes a method for treating a chronic wound, and methods for treating bacterial infections. The method for treating a chronic wound includes mechanically debriding a chronic wound, and applying a formulation to the wound for 5 to 60 seconds, the formulation including: phenolsulfonic acid—37% by weight; guaiacolsulfonic acid—24% by weight; free sulfuric acid—29% by weight; and water—10% by weight. | 2017-10-05 |
20170281573 | MEDICINAL COMPOSITION FOR ENHANCED DELIVERY OF TRITERPENES - The present disclosure relates to self-emulsifying oral compositions for enhanced absorption of poorly water soluble triterpenes, such as pentacyclic triterpene acids, either in substantially pure form or as a constituents of herbal extracts. | 2017-10-05 |
20170281574 | Method and Kit for Treating a Solid Tumor and Associated Desmoplasia - A kit for treating a human patient with a solid tumor with a desmoplasia associated therewith having: (1) a container of and effective amount of a CCNp37 (SEQ ID No. 37), CCNp38 (SEQ ID No. 38) or a combination of CCNp37 and CCNp38 (SEQ ID Nos. 37 and 38); (2) a container of an effective amount of a chemotherapeutic agent or an immunotherapeutic agent; and (3) instructions for administering these components which can involve a pretreatment with the CCNp37 (SEQ ID No. 37), CCNp38 (SEQ ID No. 38) or a combination of CCNp37 and CCNp38 (SEQ ID Nos. 37 and 38) to a patient in need thereof. | 2017-10-05 |
20170281575 | BLT2 AGONISTS FOR THE TREATMENT OF PAIN - The present invention pertains to novel analgesics useful for treating pain. BLT2 agonists were found to desensitize TRPV1 mediated signaling in sensory neurons. Thus the invention provides BLT2 agonists as novel pain therapeutics. Additional aspects of the invention pertain to combinations of BLT2 agonists with BLT1 antagonists for treating pain in subjects. Pharmaceutical compositions and kits comprising the new analgesics of the invention are furthermore provided. | 2017-10-05 |
20170281576 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS - A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose. | 2017-10-05 |
20170281577 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS - A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose. | 2017-10-05 |
20170281578 | METHODS FOR TREATING METABOLIC DISTURBANCES - In some aspects, the present invention provides a composition comprising a powder or mixture comprising from about 10 meq to 50 meq of potassium, 5 meq to 25 meq of magnesium, and from about 18 meq to 90 meq of citrate and uses of the same to prevent or treat metabolic disturbances of thiazide or chlorthalidone. | 2017-10-05 |
20170281579 | COMPOSITIONS AND METHODS FOR TREATING REFRACTORY SEIZURES - The present invention relates to the field of seizures. More specifically, the present invention provides compositions and methods for treating refractory seizures in neonates. In one embodiment, the method comprises the steps of (a) administering to the patient an amount of a KCC2 agonist and/or trkB antagonist effective to restore KCC2 expression to normal physiological levels; and (b) administering to the patient an effective amount of an anti-seizure medication. | 2017-10-05 |
20170281580 | TOPICAL DICLOFENAC SODIUM COMPOSITIONS - The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium in high amounts, and methods for their use. Said compositions represent emulsion-gels as well as gels with unique properties such as high skin penetration, no irritation, high stability, complete dissolution of the active and effective pain relief. The invention also provides methods for treating pain or inflammation in a mammalian subject in need thereof, including acute and chronic pain or inflammation; and kits therefor. | 2017-10-05 |
20170281581 | SPORTS HEALTH PERFORMANCE COMPOSITION BACKGROUND - A topical composition that includes L-arginine that is used as a sports health composition. The composition can further include forskolin. Disclosed is a method of using the topical composition. | 2017-10-05 |
20170281582 | ENHANCER FOR EATING ACTIVITY AND/OR GASTROINTESTINAL ACTIVITY - An agent for secreting ghrelin, comprising ornithine or a salt thereof as an active ingredient, an agent for enhancing eating activity, comprising ornithine or a salt thereof as an active ingredient, and an agent for enhancing gastrointestinal activity, comprising ornithine or a salt thereof as an active ingredient. | 2017-10-05 |
20170281583 | METHODS FOR TREATING BRAIN INJURY - The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). | 2017-10-05 |
20170281584 | Misoprostol Dispersible Tablet - The present invention relates to a solid pharmaceutical formulation comprising misoprostol or a pharmaceutically acceptable salt thereof. In particular, the invention relates to a dispersible tablet comprising misoprostol or a pharmaceutically acceptable salt thereof. | 2017-10-05 |
20170281585 | METHODS FOR THE TREATMENT OF SIALORRHEA - The present invention provides safe and effective methods for the treatment of sialorrhea (excessive drooling) by administering an effective amount of N-desethyloxybutynin, or an optical R- or S-isomer thereof or a pharmaceutically acceptable salt thereof. | 2017-10-05 |
20170281586 | SOLID MOLECULAR DISPERSION OF FESOTERODINE HYDROGEN FUMARATE AND POLYMERIC BINDER - The present invention relates to solid molecular dispersion of fesoterodine hydrogen fumarate and a polymeric binder. The invention also relates to an inert core bead or particle which is coated with said solid molecular dispersion and to pharmaceutical formulations comprising such coated beads or particles. | 2017-10-05 |
20170281587 | ERYTHROCYTE FUNCTION IMPROVING AGENT - An object of the present invention is to provide an agent for improving red blood cell function which has both high antioxidant action and high ability to migrate into red blood cells, and can effectively protect red blood cells against oxidative stress. Cucurbitaxanthin A and/or a derivative thereof has an ability to migrate into red blood cells significantly higher than that of the other carotenoids reported to migrate into red blood cells, and can effectively protect red blood cells against oxidative stress, and thus, is effective as an agent for improving red blood cell function. | 2017-10-05 |
20170281588 | Compositions and Methods for Treating Epithelial Cancer - The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin. | 2017-10-05 |
20170281589 | USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION - Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection. | 2017-10-05 |
20170281590 | Methods of Reducing Blood Lactate Concentration - The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance. | 2017-10-05 |
20170281591 | PRODRUG OF GREEN TEA EPIGALLOCATECHIN-3-GALLATE (PRO-EGCG) FOR USE IN THE TREATMENT OF ENDOMETRIOSIS - Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin- | 2017-10-05 |
20170281592 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS - The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents. | 2017-10-05 |
20170281593 | Methods of Treating Fatty Liver Disease - The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs. | 2017-10-05 |
20170281594 | METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS IN A MAMMAL - A topical drug composition for treating a β-catenin-mediated disorder in a mammal is provided comprising a Nefopam compound selected from Nefopam, or a functionally equivalent analogue, prodrug, salt or solvate thereof. | 2017-10-05 |
20170281595 | FORMULATION AND METHOD TO INDUCE A DEEP STATE OF RELAXATION - A relaxation formulation structured to induce a deep state of relaxation in a person comprises amounts of tryptophan, melatonin, vitamin B3, and vitamin B6. Another relaxation formulation also includes an amount of tyrosine, and yet another formulation includes an amount of vitamin B12. At least one embodiment of a relaxation formula comprises a physiologically effective amount of gamma-aminobutyric acid (“GABA”). A delivery system is provided to facilitate administration of the relaxation formulation to a person. The delivery system may include an edible high carbohydrate matrix, such as a chocolate brownie. Alternatively, the delivery system may comprise an inert vaporizable compound to allow the components of the relaxation formulation to be inhaled directly into the lungs of a person. Other delivery systems include an aqueous sublingual spray and a beverage. | 2017-10-05 |
20170281596 | PHARMACEUTICAL COMBINATION CONTAINING AN ANALGESIC AGENT AND AN ANTISPASMODIC AGENT - “PHARMACEUTICAL COMBINATION CONTAINING AN ANALGESIC AGENT AND AN ANTISPASMODIC AGENT”, whose analgesic agent is the Ketorolac Tromethamine, which is physically isolated from the antispasmodic agent and whose antispasmodic active ingredient, in combination with the analgesic agent Ketorolac Tromethamine, is Hyoscine, Pargeverine, Tolterodine, Mebeverine or Papaverine. Both the analgesic agent Ketorolac Tromethamine and the antispasmodic agent are combined in separate and immediate release form. The analgesic agent Ketorolac Tromethamine can also be found in the present combination in separate and immediate release form, while the combined antispasmodic agent is presented in equally separate, but programmed release form. The active ingredient Ketorolac Tromethamine is in a ratio between 2.5% and 20% by weight and the antispasmodic active ingredient is in a ratio between 2.5% and 20% by weight. | 2017-10-05 |
20170281597 | METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOI- SOINDOLINE-1,3-DIONE - Stereomerically pure (+)-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 2017-10-05 |
20170281598 | METHODS AND COMPOSITIONS FOR TREATING CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE - The present invention provides methods for treating and preventing the reoccurrence of | 2017-10-05 |
20170281599 | AMORPHOUS FORM OF DACLATASVIR AND ITS SALTS AND PROCESS FOR PREPARATION THEREOF - This relates to an amorphous form of daclatasvir and its salts and process for preparation thereof. In particular, it relates to an amorphous form of daclatasvir and daclatasvir dihydrochloride. It also relates to pharmaceutical compositions comprising an amorphous form of daclatasvir or daclatasvir dihydrochloride for oral administration for treatment of Hepatitis C virus (HCV). | 2017-10-05 |
20170281600 | INTRAVENOUS FORMULATION AND LC/MS/MS ANALYSIS METHOD FOR GMC1 - Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors. | 2017-10-05 |
20170281601 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 2017-10-05 |
20170281602 | SOLID FORMS OF (S)-2-METHOXY-3--PROPIONIC ACID AND OF SALTS THEREOF - The present invention relates to solid forms of (S)-2-methoxy-3-{442-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxyl-benzo[b]thiophen-7-yl}-propionic acid, and of salts of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid. | 2017-10-05 |
20170281603 | THIAZOLIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS - Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family. | 2017-10-05 |
20170281604 | COMPOSITIONS AND METHODS FOR TREATING PLASMA CELL DISORDERS AND B-CELL PROLYMPHOCYTIC DISORDERS - Disclosed herein are methods of treating conditions, which may be associated with elevated levels of plasma cells and/or B-cells, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof. | 2017-10-05 |
20170281605 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS IN RESPONDERS - A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising administering to said subject an effective amount of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or pharmaceutically acceptable salt thereof, wherein said subject is a treatment responder. In certain embodiments, said subject is a subject with definite amyotrophic lateral sclerosis, a subject with amyotrophic lateral sclerosis symptom onset duration of less than about 18 months, a subject with a high level of serum creatinine, a subject with concomitant riluzole administration and combinations thereof. | 2017-10-05 |
20170281606 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. | 2017-10-05 |
20170281607 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES - This invention relates to compositions and methods for treating type I diabetes. Compositions of the invention include active compounds such as harmine, INDY, or derivatives thereof to induce reproduction of beta cells. These active compounds are provided in amounts that have poor clinical efficacy on their own, but when administered at a sub-threshold dose in combination with compounds such as insulin, which helps to maintain steady levels of insulin in the body; metformin, which decreases glucose levels; and repaglinide, which increases insulin production, allow for the slow and steady increase of beta cells. | 2017-10-05 |
20170281608 | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions - Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy. | 2017-10-05 |
20170281609 | Granulate Formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and Method of Making the Same - The disclosure relates to granulate formulations of pirfenidone and methods of making such formulations. | 2017-10-05 |
20170281610 | TOPICAL RETINOID COMPOSITIONS - The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc. | 2017-10-05 |
20170281611 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES - Provided herein are quinolines, e.g., a compound of Formula (I) or (IB), pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca | 2017-10-05 |
20170281612 | Methods for the Treatment of Cystic Fibrosis - The present invention is directed to a method of treating or lessening the severity of cystic fibrosis in a patient, comprising the step of administering to said patient an effective amount of an inhibitor of S-nitrosoglutathione reductase (GSNOR) in combination with one or more secondary active agents. | 2017-10-05 |
20170281613 | Combination Therapy - Described herein are compounds and compositions for treating glaucoma and/or reducing introcular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt. | 2017-10-05 |
20170281614 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2017-10-05 |